A subsidiary of Jiangxi Jemincare Group Co. Ltd. has out-licensed global rights to its androgen receptor degrader JMKX-002992 to Roche Holding AG and its subsidiary Genentech Inc. in a deal worth up to $650 million. Read More
Everest Medicines Ltd. has inked an agreement with Gilead Sciences Inc. to pass the latter’s subsidiary, Immunomedics Inc., exclusive rights to develop and commercialize Trodelvy (sacituzumab govitecan) in greater China, Singapore, Indonesia, Philippines, Vietnam, Thailand, Malaysia and Mongolia. Read More
Alterity Therapeutics Ltd. has begun phase II trials with its lead candidate, ATH-434, in multiple system atrophy, a rare and highly debilitating Parkinsonian disorder. Read More
It’s been a patchy year for vaccine specialist Valneva SE, in which it saw European orders for its delayed
COVID-19 vaccine dry up but then received a €90.5 million (US$92.1 million) investment from Pfizer Inc. as its Lyme disease vaccine entered phase III. The firm has now hit another setback after the U.S. Department of Defense decided not to take an option for a second year in contract to supply a Japanese encephalitis vaccine, Ixiaro. Read More
Staidson Biopharmaceuticals Co. Ltd. is testing a combination of two monoclonal antibodies (MAb), STSA-1002 and STSA-1005, in China for the potential treatment of people with severe-to-critical COVID-19. Read More
Epigenic Therapeutics Co. Ltd., a company developing epigenomic-focused gene therapies in multiple indications, has raised $20 million across angel and pre-series A rounds to support preclinical studies, early stage research, and growth for its team. Read More
Western Australia’s private investment group Tattarang has launched a new AU$250 million (US$173.6 million) investment fund called Tenmile that will invest in early stage Australian biotech and med-tech companies. One of Australia’s largest private investment groups, Tattarang is owned by the Forrest family and has five business divisions made up of real estate, agriculture, energy, mining and hospitality. Read More
The Project to Accelerate New Treatments for Tuberculosis is progressing two investigational tuberculosis combination treatment regimens into phase II trials under a joint development agreement. Read More
Growing the international competitiveness of Taiwan’s biotech sector is one of six key strategies Taiwan’s government is heavily invested in, Taiwan President Tsai Ing-wen told attendees via video during the recent BIO Asia-Taiwan conference in Taipei. Read More
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: Antengene, Arcturus, CSL Behring, Curevac, Gannex, Genexine, I-Mab, Jiangsu Recbio Technology, Revive, Sirnaomics, Tessa. Read More
Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: Aarvik, Antisense, Daiichi Sankyo, Epiaxis, Everest Medicines, Gilead Sciences, J Ints Bio, Peptilogics, Seagen. Read More
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Arrowhead, Astellas, Aum, Bridge, Celltrion Healthcare, Genfleet, Index, Junshi, Kyowa Kirin, Novavax, Nuance, Organon, Samsung, SK, Verona. Read More
